In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Roche targets multi-drug resistant Gram-negative bacteria in Discuva deal; extended

Executive Summary

Just three months after penning a deal with Polyphor Ltd., signaling its interest to get back involved in antibiotics after focusing on broad-spectrum products, Roche and UK drug discovery start-up Discuva Ltd. forged an agreement around multi-drug resistant Gram-negative bacterial infections. The Big Pharma will have global rights to resulting candidates.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
      • Molecular Diversity
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies